An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Stopped early · Phase 3

Conditions studied: Parkinson's Disease

In brief

This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.

Key facts

Study ID

NCT00199381

Run by

Kyowa Kirin, Inc.

People needed

504

Starts

2005-10-01

Expected to finish

2008-10-01

Last updated by the study team

2024-05-17

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of study 6002-INT-001
• Not of childbearing potential

You may not qualify if…

• Cancer within 5 years of enrollment
• ALT/AST levels > 2.5 times ULN

Where it is running

• Kyowa Pharmaceutical Inc. — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.